Bayer: Prostatic Neoplasms trials

The registry lists 75 Prostatic Neoplasms studies with Bayer as lead sponsor. 11 are open to participants now and 12 have results posted.

Phase 1 12Phase 2 14Phase 3 8Phase 4 2No phase 41(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in IndiaNot yet recruitingNCT07806591
• A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or DarolutamideRecruitingNCT07672119
• An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT TreatmentRecruitingNCT07538843
• A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.RecruitingNCT07450599Phase 2
• How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in GermanyRecruitingNCT07395804
• A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical PracticeRecruitingNCT07344779
• An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in AustraliaRecruitingNCT07223372
• A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate CancerRecruitingNCT06661122
• An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in KoreaRecruitingNCT06334120
• First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingNCT06217822Phase 1
• A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)RecruitingNCT05348876Phase 4
• A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With EnzalutamideCompletedNCT05526248Phase 2Results posted
• A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.CompletedNCT05059236Phase 2Results posted
• Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerCompletedNCT04736199Phase 3Results posted
• Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT02799602Phase 3Results posted
• Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerCompletedNCT02200614Phase 3Results posted
• Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate CancerCompletedNCT02141438Results posted
• Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild SymptomsCompletedNCT02043678Phase 3Results posted
• A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)CompletedNCT02034552Phase 2Results posted
• Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the BoneCompletedNCT02023697Phase 2Results posted
• Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone MetastasesCompletedNCT01934790Phase 1/2Results posted
• A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)CompletedNCT01106352Phase 1/2Results posted
• A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesCompletedNCT00699751Phase 3Results posted
• A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsTerminatedNCT07406282
• An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical CareCompletedNCT06874114
• An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical CareCompletedNCT06498921
• An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United StatesCompletedNCT06204302
• A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06052306Phase 1
• An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World SettingsCompletedNCT06013475
• A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate CancerActive, not recruitingNCT06010914
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesActive, not recruitingNCT05794906Phase 3
• An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World SettingsCompletedNCT05362149
• A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone LevelsTerminatedNCT05301062
• A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication CompletelyCompletedNCT05202301
• Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate CancerCompletedNCT05171387Phase 2
• A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate CancerCompletedNCT05149131
• A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in EuropeCompletedNCT04925180
• A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its SafetyCompletedNCT04681144
• RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Active, not recruitingNCT04597125Phase 4
• A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 BeforeCompletedNCT04587427
• A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the BonesCompletedNCT04521361Phase 1
• EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)CompletedNCT04516161
• Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the BodyCompletedNCT04281147
• PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEnCompletedNCT04256993
• Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the BoneCompletedNCT04232761
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are DescribedActive, not recruitingNCT04122976
• Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).CompletedNCT03896984
• Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03724747Phase 1
• Multi-academic Center Study of Xofigo PatientsCompletedNCT03419442
• Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review StudyWithdrawnNCT03325127
• Treatment Satisfaction With Ra-223 in JapanCompletedNCT03315260
• Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male VolunteersCompletedNCT03237416Phase 1
• Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in SwedenCompletedNCT02963675
• Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the USCompletedNCT02788409
• Treatment Patterns in Metastatic Prostate CancerCompletedNCT02729103
• Second Primary Cancers in Patients With Castration Resistant Prostate CancerCompletedNCT02702908
• Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare PopulationCompletedNCT02518698
• Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) SubjectsCompletedNCT02363855Phase 1
• Japanese BAY88-8223 Monotherapy Phase II StudyCompletedNCT01929655Phase 2
• Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone MetastasisCompletedNCT01810770Phase 3
• First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate CancerCompletedNCT01723475Phase 1
• Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone MetastasesCompletedNCT01618370Phase 3
• Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese PatientsCompletedNCT01565746Phase 1
• Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone MetastasesNo longer availableNCT01516762
• Study to Investigate Adherence of Patients to Clodronate (Bonefos) TreatmentCompletedNCT01198457
• Androcur Non-interventional Study Among Patients With Carcinoma of the ProstateTerminatedNCT00919022
• Bonefos and the Consumption of AnalgesicsCompletedNCT00909142
• Androcur Effects on Quality of LifeCompletedNCT00908674
• Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)CompletedNCT00751205Phase 2
• Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the SkeletonCompletedNCT00748046Phase 1
• PK in Pts With HRPC & Skeletal MetastesCompletedNCT00667537Phase 1
• BAY88-8223, Does Response Study in HRPC PatientsCompletedNCT00667199Phase 2
• A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate CancerCompletedNCT00459654Phase 2
• ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate CancerCompletedNCT00350051Phase 2
• BAY88-8223, Dose Finding Study in Patients With HRPCCompletedNCT00337155Phase 2